NCT02302339 2019-09-06A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced MelanomaCelldex TherapeuticsPhase 2 Terminated132 enrolled 16 charts
NCT03326258 2018-07-18Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryNational Cancer Institute (NCI)Phase 1/2 Withdrawn